Cargando…
Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
BACKGROUND: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of rpoB gene using five overlapping probes represented as...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993378/ https://www.ncbi.nlm.nih.gov/pubmed/32000702 http://dx.doi.org/10.1186/s12879-020-4817-2 |
_version_ | 1783493019885895680 |
---|---|
author | Alemu, Ayinalem Tadesse, Mengistu Seid, Getachew Mollalign, Helina Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Amare, Misikir Dagne, Biniyam Diriba, Getu Yenew, Bazezew Getu, Melak Zerihun, Betselot |
author_facet | Alemu, Ayinalem Tadesse, Mengistu Seid, Getachew Mollalign, Helina Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Amare, Misikir Dagne, Biniyam Diriba, Getu Yenew, Bazezew Getu, Melak Zerihun, Betselot |
author_sort | Alemu, Ayinalem |
collection | PubMed |
description | BACKGROUND: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of rpoB gene using five overlapping probes represented as Probe A (codons 507–511), Probe B (codons 512–518), Probe C (codons 518–523), Probe D (codons 523–529) and Probe E (codons 529–533). In this review, we assessed the frequency of missed probe types for Rifampicin Resistance results. METHODS: Data were reviewed from specimens received and tested using Xpert® MTB/RIF assay at Ethiopian National Tuberculosis Reference Laboratory, in Addis Ababa from 15 July 2016 to 31 December 2018 retrospectively. All archived data were reviewed carefully to describe missed probe types and the quantity of DNA in the sample. RESULTS: A total of 100 specimens were reported as MTB Detected Rifampicin Resistance Detected by Xpert® MTB/RIF assay. More than half (55%) of these results were reported from male patients. The median age was 28.0 years (5 months to 88 years). Majorities (62%) of the cases were detected from sputum. Among the total of 38 extrapulmonary samples, lymph node aspirates were accounted for 50% (19/38). The most common mutations (81.0%) were found in the Probe E region followed by Probe D (10.0%), and Probe B (3.0%). Mutations in Probe A and Probe C regions were not observed. However, six (6.0%) Rifampicin resistance cases were found without any missed probe type. The delta Ct max is ≥4.3. No specimen yielded Rifampicin resistance associated with more than one probe failure or mutation combinations. CONCLUSION: Mutations associated with Probe E (codons 529–533) region were identified as the commonest rpoB gene mutations. The Rifampicin resistance results found without any identified missing probe needs further study. The lower DNA amount was observed in extrapulmonary specimens compared with sputum. |
format | Online Article Text |
id | pubmed-6993378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69933782020-02-04 Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia Alemu, Ayinalem Tadesse, Mengistu Seid, Getachew Mollalign, Helina Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Amare, Misikir Dagne, Biniyam Diriba, Getu Yenew, Bazezew Getu, Melak Zerihun, Betselot BMC Infect Dis Research Article BACKGROUND: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of rpoB gene using five overlapping probes represented as Probe A (codons 507–511), Probe B (codons 512–518), Probe C (codons 518–523), Probe D (codons 523–529) and Probe E (codons 529–533). In this review, we assessed the frequency of missed probe types for Rifampicin Resistance results. METHODS: Data were reviewed from specimens received and tested using Xpert® MTB/RIF assay at Ethiopian National Tuberculosis Reference Laboratory, in Addis Ababa from 15 July 2016 to 31 December 2018 retrospectively. All archived data were reviewed carefully to describe missed probe types and the quantity of DNA in the sample. RESULTS: A total of 100 specimens were reported as MTB Detected Rifampicin Resistance Detected by Xpert® MTB/RIF assay. More than half (55%) of these results were reported from male patients. The median age was 28.0 years (5 months to 88 years). Majorities (62%) of the cases were detected from sputum. Among the total of 38 extrapulmonary samples, lymph node aspirates were accounted for 50% (19/38). The most common mutations (81.0%) were found in the Probe E region followed by Probe D (10.0%), and Probe B (3.0%). Mutations in Probe A and Probe C regions were not observed. However, six (6.0%) Rifampicin resistance cases were found without any missed probe type. The delta Ct max is ≥4.3. No specimen yielded Rifampicin resistance associated with more than one probe failure or mutation combinations. CONCLUSION: Mutations associated with Probe E (codons 529–533) region were identified as the commonest rpoB gene mutations. The Rifampicin resistance results found without any identified missing probe needs further study. The lower DNA amount was observed in extrapulmonary specimens compared with sputum. BioMed Central 2020-01-30 /pmc/articles/PMC6993378/ /pubmed/32000702 http://dx.doi.org/10.1186/s12879-020-4817-2 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Alemu, Ayinalem Tadesse, Mengistu Seid, Getachew Mollalign, Helina Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Amare, Misikir Dagne, Biniyam Diriba, Getu Yenew, Bazezew Getu, Melak Zerihun, Betselot Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia |
title | Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia |
title_full | Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia |
title_fullStr | Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia |
title_full_unstemmed | Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia |
title_short | Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia |
title_sort | does xpert® mtb/rif assay give rifampicin resistance results without identified mutation? review of cases from addis ababa, ethiopia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993378/ https://www.ncbi.nlm.nih.gov/pubmed/32000702 http://dx.doi.org/10.1186/s12879-020-4817-2 |
work_keys_str_mv | AT alemuayinalem doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT tadessemengistu doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT seidgetachew doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT mollalignhelina doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT eshetukirubel doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT sinshawwaganeh doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT abebawyeshiwork doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT amaremisikir doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT dagnebiniyam doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT diribagetu doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT yenewbazezew doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT getumelak doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia AT zerihunbetselot doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia |